Changes in markers of inflammation and their correlation with death in patients with COVID-19 in the intensive care unit

• Published in: Cytokine (Philadelphia, Pa.) Pa.), 2024-03, Vol.175, p.156509-156509, Article 156509
• Main Authors: de Azambuja Pias Weber, Andressa, Viero, Fernanda Tibolla, Pillat, Micheli Mainardi, de Lima Gonçalves, Thissiane
• Format: Article
• Language: English
• Subjects: COVID-19; Cytokines; Humans; Inflammation; Inflammation Mediators; Intensive Care Units; Interferon-gamma; Interleukin-6; SARS-CoV-2
• ISSN: 1043-4666; 1096-0023
• DOI: 10.1016/j.cyto.2024.156509

This study aimed to characterize the changes in serum inflammatory mediators in hospitalized patients with COVID-19 correlating with death. The study includes 58 participants: i) inpatients (n = 37): patients suffering from severe acute respiratory syndrome due to COVID-19, who were admitted at Intensive Care Unit (ICU) recovered and who died and ii) control group (n = 21): community volunteers. Inflammatory mediators evaluated interleukin-2 (IL-2), interleukin-4 (IL-4), interleukin-6 (IL-6), interleukin-10 (IL-10), interleukin-17 (IL-17), interferon-gamma (IFN-γ) and interferon-gamma protein levels (IFN-γ), as well as, Urea, LDH, D-dimer, TAP/INR, AST, ALT and lymphocytes. Our results suggest that high levels of inflammatory markers, such as pro-inflammatory cytokines, and laboratory parameters, such as low levels of lymphocytes and high levels of IL-6, are associated with disease severity, especially in individuals who died. Constant measurement and monitoring of these inflammatory parameters is an effective tool in clinical practice, and it can help choosing appropriate therapies during the course of the disease.